rs201050491
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_014625.4(NPHS2):c.182C>T(p.Ala61Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000937 in 1,596,352 control chromosomes in the GnomAD database, including 12 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another nucleotide change resulting in same amino acid change has been previously reported as Likely benignin UniProt. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A61T) has been classified as Uncertain significance.
Frequency
Consequence
NM_014625.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NPHS2 | NM_014625.4 | c.182C>T | p.Ala61Val | missense_variant | 1/8 | ENST00000367615.9 | NP_055440.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NPHS2 | ENST00000367615.9 | c.182C>T | p.Ala61Val | missense_variant | 1/8 | 1 | NM_014625.4 | ENSP00000356587.4 | ||
NPHS2 | ENST00000367616.4 | c.182C>T | p.Ala61Val | missense_variant | 1/7 | 1 | ENSP00000356588.4 |
Frequencies
GnomAD3 genomes AF: 0.00524 AC: 798AN: 152196Hom.: 6 Cov.: 32
GnomAD3 exomes AF: 0.00115 AC: 246AN: 213816Hom.: 3 AF XY: 0.000824 AC XY: 98AN XY: 118934
GnomAD4 exome AF: 0.000483 AC: 698AN: 1444042Hom.: 6 Cov.: 31 AF XY: 0.000401 AC XY: 288AN XY: 718286
GnomAD4 genome AF: 0.00524 AC: 798AN: 152310Hom.: 6 Cov.: 32 AF XY: 0.00498 AC XY: 371AN XY: 74472
ClinVar
Submissions by phenotype
not specified Benign:3
Benign, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Benign, no assertion criteria provided | clinical testing | Genetic Services Laboratory, University of Chicago | Jun 13, 2022 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Dec 02, 2016 | - - |
not provided Benign:3
Likely benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Likely benign, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Nephrotic syndrome, type 2 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Apr 11, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at